Bone marrow mesenchymal stem cells in Waldenström Macroglobulinemia
Phenotypic and Functional Study of Bone Marrow Mesenchymal Stem Cells in Waldenström Macroglobulinemia
This project will take bone marrow samples to test how mesenchymal stem cells behave in people with Waldenström Macroglobulinemia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire, Amiens Academic / other |
| Locations | 1 site (Amiens) |
| Trial ID | NCT07471074 on ClinicalTrials.gov |
What this trial studies
Researchers will collect bone marrow samples from consenting patients with Waldenström Macroglobulinemia who require treatment and isolate mesenchymal stem cells for laboratory study. The cells will be characterized for their surface phenotype and functional properties and compared with expected normal features of the bone marrow niche. The work will explore how stromal cell abnormalities and microenvironment signals relate to disease features and common mutations such as MYD88 and CXCR4. Findings are intended to improve biological understanding of tumor–niche interactions rather than to test a therapeutic intervention.
Who should consider this trial
Good fit: Adults with a confirmed diagnosis of Waldenström Macroglobulinemia who require treatment within three months, can give informed consent, and have social security coverage are eligible.
Not a fit: Patients who do not need treatment, who have other chronic lymphoid malignancies, who have transformed histology, or who cannot undergo bone marrow sampling are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this work could clarify how the bone marrow environment supports Waldenström cells and point to biomarkers or targets for future therapies.
How similar studies have performed: Previous work has described immune-cell abnormalities in Waldenström disease and some microenvironment studies exist, but detailed functional data specifically on bone marrow mesenchymal stem cells remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with WM, meeting the diagnostic criteria defined at the 2nd WM Workshop, revised at the 9th international workshop. * Patients requiring treatment within 3 months according to the recommendations defined at the 2nd Workshop on WM. * Patients having given their consent for this study. * Affiliation to a social security scheme. Exclusion Criteria: * Patients with other chronic lymphoid hemopathies. Particular care should be taken to exclude other closely related lymphoplasmacytic proliferations, especially marginal zone lymphomas. * Patients with WM who have undergone histological transformation to a lymphoma other than diffuse large B- cell lymphoma. * Absence of consent for this study. * Patients under court protection, subjects participating in another study with an exclusion period still in progress at pre-inclusion.
Where this trial is running
Amiens
- CHU Amiens — Amiens, France (Recruiting)
Study contacts
- Study coordinator: Pierre MOREL
- Email: morel.pierre@chu-amiens.fr
- Phone: 33+3 22 45 54 19
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.